The risk for an unfavourable course of SARS-CoV-2 pneumonia rises with age and comorbidities. We report the case of an elderly female where the sum of such factors – together with massive findings in the computed tomography of the lung – led us to a therapy with hydroxychloroquine as a compassionate use. The unfavourable outcome demonstrates that – despite the enthusiasm of some authors – hydroxychloroquine is no miracle drug. The worldwide SOLIDARITY trial will help clinicians to assess the potential of the repurposed antimalarial drugs better.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Chloroquine, Hydroxychloroquine, Chest CT, compassionate use, repurposed agent.,
【저자키워드】 COVID-19, SARS-CoV-2, Chloroquine, Hydroxychloroquine, Chest CT, compassionate use, repurposed agent.,